

Hypoglycemic Effect of 70% Ethanolic Extract of *Tinosporacrispa* L. (*Bratawali*) Stem from Indonesia in Wistar Rat Induced by Alloxan

EM SUTRISNA¹, LIGAR HERVIAN², FAHRIZAL ARRIO SAHADEWA³

ABSTRACT

Introduction: Indonesian people often use *Bratawali* (*Tinosporacrispa* L.) to treat Diabetes Mellitus (DM) empirically. Based on literature, the active compound in the plant is thought to initiate insulin secretion by modulating the β -cell of Ca^{2+} concentration.

Aim: The aim of the present study is to evaluate hypoglycemic effect 70% ethanolic extracts of *Tinosporacrispa* L. (EETC) in Wistar rats induced by alloxan.

Materials and Methods: Twenty five rats were divided into 5 groups. The group I was negative control treated by aqua bidest, group II was positive control treated by glibenclamide at dose of 0.63/kg bw/day, group III was treated by EETC at dose of 500 mg/kgbw/day, group IV was treated by EETC at dose of 1000 mg/kgbw/day and group V was treated by EETC at dose of 2000 mg/kgbw/day. The fasting Blood Glucose Level (BGL)

of all rats were measured and then they were injected by alloxan at dose of 150 mg i.p. On fourth day BGL were re-measured. All rats with BGL > 200 mg/dL were treated by extract/medicine appropriated their group. This treatment was for ten days. The Fasting BGL between groups was analysed using ANOVA followed by LSD.

Results: The results of this research shows that the EETC at dose of 500 mg/kgbw/day and 2000 mg/kgbw/day can reduce fasting BGL in Wistar rats induced by alloxan significantly ($p < 0.05$). The percentage of reduction of fasting BGL at dose of 500 mg/kgbw/day and 2000 mg/kgbw/day are 44.78 ± 5.27 and 43.12 ± 4.25 respectively. EETC at dose of 500 and 2000 mg/kg bw/day allegedly able to repair the pancreatic islet cell.

Conclusion: It is concluded that the EETC reduce fasting BGL in Wistar rats induced by alloxan.

Keywords: Antidiabetic, Diabetes mellitus, Fasting blood glucose level

INTRODUCTION

Diabetes Mellitus (DM) is a disease caused by a metabolic disorder characterized by hyperglycaemia. The causes are multifactorial and include genetic, environmental and lifestyle factors [1].

Indonesia is one of the developing countries in Asia. Number of patients with DM in Indonesia was ranked fourth highest in the world after India, China and the United States. WHO Predicts an increasing number of people with diabetes mellitus from 8.426 million in 2000 to 21.257 million in 2030 [2].

Tinosporacrispa (L.) is a traditional Indonesian medicinal plant commonly planted in the yard or grows wild in the forest [3]. Empirically, Indonesian people often use *Bratawali* (*Tinosporacrispa* L.) to treat DM. Indonesian people use leaves and stems of this plant by boiling. In Indonesia this plant was known as *Bratawali*, *Andawali*, *Antawali* or *Putrawali*. This plant is large and belongs to Menispermaceae family [3].

MATERIALS AND METHODS

This research was experimental study with animal test. The study was performed in Department of Pharmacology of Medical Faculty of Universitas Muhammadiyah, Surakarta, Indonesia from September 2015 to August 2016. The study protocol was approved by the Health Research Ethics Committee of Medical Faculty of University of Muhammadiyah Surakarta with no: 182/A.1/KEPK-FKUMS/I/2016.

Plant Collection

Tinosporacrispa L. was collected from Tawangmangu, Karanganyar, Jawa Tengah, Indonesia on October 2015. The plant was confirmed by Biology of Universitas Muhammadiyah, Surakarta, Indonesia on November 2015.

Extract Preparation

Tinosporacrispa L. Stems were washed and then dried for two weeks in ambient temperature. A suitable weight of this stem was macerated by 70% ethanol for 4 days. The filtrates were evaporated by vacuum evaporation at Pharmacology laboratory of Faculty of medicine of Universitas Muhammadiyah, Surakarta.

Induction of Diabetes

The method of diabetic induction was conducted by Sutrisna research on 2015 and others research previously [4-8]. The Wistar strain rats were injected by alloxan monohydrate at dose of 150 mg/kg intra peritoneal (i.p). On fourth days, fasting BGL was measured and compared with pre injection of alloxan.

Experimental Design

Twenty five male Wistar rats weighting 175-225 g were brought from animal house of Pharmacology laboratory of faculty of Medicine of Universitas Muhammadiyah, Surakarta. These rats were divided by into five groups of five rats each. The group I was negative control (aquabidest), group II was positive control (treated by glibenclamide 0.63 mg/kg/day), group III (treated by EETC at dose of 500 mg/kg/day), group IV (treated by EETC at dose of 1000 mg/kg/day) and group V (treated by EETC at dose of 2000 mg/kg/day). The fasting BGL of all rats were measured and then they were injected alloxan at dose of 150 mg i.p. This dose refers to our previous research [6]. On day four fasting BGL were re-measured. All rats with fasting BGL ≥ 200 mg/dL were treated by extract/medicine according to their group. This treatment was done for ten days. On day 15, all rats were measured for fasting BGL and then sacrificed by cervical dislocation. The pancreas was subjected to histopathological examination with Haematoxylin-eosin staining. The observation was done by light microscope with 400x magnifications. Histopathology of pancreas was evaluated qualitatively.

STATISTICAL ANALYSIS

The fasting BGL are presented as mean±SD. Fasting BGL between groups was analysed using ANOVA followed by LSD. The Histopathology of pancreas is evaluated qualitatively.

RESULTS

Effect of EETC on Blood Glucose Level

The effect of EETC on fasting BGL is documented in [Table/Fig-1]. Based on [Table/Fig-1], it can be seen that the fasting BGL increased on day 4. This is caused by alloxan injection. On day 14 (after 10 days treatment), the fasting BGL of all groups reduced.

| Groups | Fasting BGL | | |
|--------------------------------|----------------------------------|---------------------------------|-------------------------------------|
| | Day 0 (before alloxan injection) | Day 4 (after alloxan injection) | Day 14 (after 10 days of treatment) |
| Negative control | 103.67±6.44 | 219.00±86.26 | 159.6±4.68 |
| Positive control | 92.50±9.18 | 202.33±13.73 | 89.30±11.36* |
| EECT at dose of 500 mg/kg/day | 128.33±14.98 | 257.33±18.70 | 103.8±9.15* |
| EECT at dose of 1000 mg/kg/day | 128.67±10.28 | 148.33±29.65 | 96.80±8.99 |
| EECT at dose of 2000 mg/kg/day | 140.50±10.07 | 293.67±99.40 | 121.3±4.79* |

[Table/Fig-1]: The effect of EETC on fasting blood glucose level.

Values of fasting BGL are expressed mean±SD.

*significant difference with negative control on $p < 0.05$ by LSD test.

Based on [Table/Fig-1] the fasting BGL on day 14 are analysed by ANOVA test. There is significant difference in fasting BGL with p -value < 0.05 .

From [Table/Fig-1], the percent of reduction of BGL was calculated.

| Groups | The percent of reduction of fasting BGL (%) |
|--------------------------------|---|
| Positive control | 39.43±4.62 |
| EECT at dose of 500 mg/kg/day | 44.78±5.27** |
| EECT at dose of 1000 mg/kg/day | 10.65±2.81 |
| EECT at dose of 2000 mg/kg/day | 43.12±4.25** |

[Table/Fig-2]: The percentage of reduction of BGL.


**Not significantly difference with negative control on $p < 0.05$ by LSD test.

The result of percent of reduction of BGL can be seen in [Table/Fig-2].

From [Table/Fig-2], it can be concluded that the percent of reduction of BGL EECT at dose of 500 mg/kg BW/day and EECT at dose of 2000 mg/kg BW/day is equivalent to positive control.

The Effect of EETC on Histopathology of Pancreas

After measurement of fasting BGL on day 14, rats were killed by cervical dislocation. The pancreas was taken for histopathology



[Table/Fig-3]: The histopathological staining by HE of rat pancreas. 1. Negative control group, 2. EETC at dose of 500 mg/kg/day, 3. EETC at dose of 1000 mg/kg/day, 4. EETC at dose of 2000 mg/kg/day. a) Necrosis, b) inflammation cell, c) Vacuole (H&E, 400X)

examination with H&E staining. The result of this can be seen in [Table/Fig-3].

From [Table/Fig-3], It can be seen that it there was no islet cell necrosis in group I & III (EECT at dose of 500 and 2000 mg/kg bw/day). EETC at dose of 500 and 2000 mg/kg bw/day was allegedly able to repair the pancreatic islet cell.

DISCUSSION

The results of this research show that 70% of EETC reduces fasting BGL in Wistar strain rats induced by alloxan. This research uses alloxan monohydrate for induction of diabetes. Alloxan as an inducing agent of diabetes refers to research conducted by several previous studies [4-8].

Based on histopathological results, this extract can repair pancreas islet cell. Various studies have showed that the *T. crispa* reduced blood glucose level in animal test and patient [9-12]. The aqueous extract of *Tinosporacrispa* stems at dose of 4 g/L in drinking water for 2 weeks improve glucose tolerance in alloxan diabetic rats [9]. The research by Sari SI at 2014 stated the tinokrisposid (compound of *T. crispa* stem) at dose of 5, 10 and 20 mg/kg can decrease blood glucose level in diabetic rats significantly ($p < 0.05$) [10]. Research by Umamaheswari S and Prince BM, 2007 demonstrated that the *Tinosporacordifolia* root extract lowers plasma thiobarbituric acid reactive substances hydroperoxides, glycosylated hemoglobin (HbA1c) and ceruloplasmin levels in diabetic rats models [11]. Noipha K et al., found that *T. crispa* extract increases the level of GLUT1, AMPK α , and PPAR transport transporters, thus increasing glucose uptake in L6 myotubes [12]. The treatment with dry powder of *T. crispa* at dose of 250 mg twice daily on patients with metabolic syndrome decreased fasting blood glucose significantly from the baseline [13].

Several compounds suspected in *Tinosporacrispa* are flavones and flavonoids, tannin [14,15], terpenoids [16], and alkaloids [17]. Flavonoids are natural antioxidants that can act as a reducing hydroxyl radicals, superoxide and peroxy radicals. The mechanism of antioxidants of flavonoid is by capturing the ROS directly and preventing the regeneration of ROS. Indirectly, flavonoids can increase activity of cellular antioxidant enzyme. Flavonoids effectively act as Scavenger reactive species, such as superoxide, peroxy radicals and peroxy nitrite by transferring atomic H + [18]. The mechanism of flavonoid antioxidant is thought to be: a) scavenging ROS, b) inhibiting enzymes involved in ROS formation c) protection of antioxidant defenses [19,20]. Research by Noor H, Ashcroft SJ found that the active compound *T. crispa* L was suspected to initiate insulin secretion by modulating the β -cell of Ca $^{2+}$ concentration [9].

The stems of *T. crispa* L. Contain triterpens. Two triterpenes of *T. crispa* L. are cycloeucalenol and cycloeucalenone [21]. Triterpenoids or steroids are compounds that have a role as an antioxidant. The Antioxidant mechanism of triterpenoids is to scavenging of reactive species, such as superoxide, and metal chelate (Fe $^{2+}$ and Cu $^{2+}$) [22]. Triterpenoids have also the ability to maintain of the stability of liver cell membrane [23].

LIMITATION

The present study only measures the pancreatic histopathological changes. Biochemical changes due to pancreatic damage (serum amylase or lipase) need to be evaluated.

CONCLUSION

EETC at dose of 500 mg/kgbw/day and 2000 mg/kgbw/day can reduce fasting blood glucose level in Wistar rats induced by alloxan. EETC at dose of 500 and 2000 mg/kg bw/day allegedly able to repair the pancreatic islet cell. It is concluded that the EETC can be developed as antidiabetic agent.

ACKNOWLEDGEMENTS

We thank to Universitas Muhammadiyah, Surakarta, Indonesia as funder of this research.

REFERENCES

- [1] Power AC. Diabetes mellitus, in: Harrison et al. Principal of Internal medicine, by 16th ed. New York: McGraw-Hill Medical Publishing Division, 2005, pp. 2152-53.
- [2] World Health Organization. Prevalence of diabetes in the WHO South-East Asia Region, accessed on March 2015. http://www.who.int/diabetes/facts/world_figures/en/index5.html.
- [3] Dalimartha, Setiawan. Atlas of Indonesia Medicinal Plant. Jakarta: Puspa Swara. 2008:10-13.
- [4] Sutrisna EM, Sujono TA. The combination of Belimbing Wuluh fruit (*Averrhoa bilimbi* L.) and leaves of TapakDara (*Catharanthus roseus* G.) from Indonesia as a candidate hypoglycemic agents and thin layer chromatography profiles. *Biomedical & Pharmacology Journal*. 2015;8(1):39-46.
- [5] Chaudhary P, Goel BH, Ghosh AK. Antidiabetic activity of *Adina cordifolia* (Roxb) leaves in alloxan induced diabetic rats. *APJTB*. 2012;2(3):S1630-32.
- [6] Jawla S, Kumar Y, Khan MSY. Hypoglycemic activity of *Bougainvillea spectabilis* stem bark in normal and alloxan-induced diabetic rats. *APJTB*. 2012;2(2):S919-23.
- [7] Shah NA, Khan MR. Antidiabetic effect of *Sida Cordata* in Alloxan induced diabetic rats. *Bio Med Research International*. 2014; 2014:1-15.
- [8] Viana GS, Medeiros AC, Lacerda AM, Leal LK, Vale TG, Matos FJ. Hypoglycemic and anti-lipemic effects of the aqueous extract from *Cissampelos*. *BMC Pharmacol*. 2004;8:04-09.
- [9] Noor H, Ashcroft SJ. Antidiabetic effects of *Tinosporacrispa* in rats. *J Ethnopharmacol*. 1989;27(1-2):149-61.
- [10] Sari SI. Uji aktivitas antidiabetes senyawa tinokrisposid dari batang brotowali (*Tinosporacrispa* (L.) Miers) terhadap mencit putih jantan dengan metoda tes toleransi glukosa oral dilanjutkan induksi aloksan. 2014. Thesis, Andalas University. <http://repository.unand.ac.id/id/eprint/21942>
- [11] Umamaheswari S, Prince PSM. Antihyperglycaemic effect of 'Ilogen Excel', an ayurvedic herbal formulation in streptozotocin-induced diabetes mellitus. *Acta Pol Pharm*. 2007;64(1):53-61.
- [12] Noipha K, Ninla-Aesong P. The Activation of GLUT1, AMPK alpha and PPAR gamma by *Tinosporacrispa* in L6 Myotubes. *Spatula DD*. 2011;1(4):245-49.
- [13] Sriyapai C, Dhumma-Upakorn R, Sangwatanaroj S, Kongkathip N, Krittiyanunt S. Hypoglycemic effect of *Tinosporacrispa* dry powder in outpatients with metabolic syndrome at King Chulalongkorn Memorial Hospital. *J Health Res*. 2009;23(3):125-33.
- [14] Lin YH. Studies on the chemical constituents of *Tinosporacrispa* and synthesis of the analogous of Penta-o-Galloyl-d-Glucopyranose. Masters dissertation, China Medical University, 2009:34-40.
- [15] UmiKalsom Y, Noor H. Flavone O-glycosides from *Tinosporacrispa*. *Fitoterapia*. 1995;66:280.
- [16] Kongkathip N, Dhumma-Upakorn P, Kongkathip B, Chawanoraset K, Sangchomkao P, Hatthakitpanichakul S. Study on cardiac contractility of cycloecalenol and cycloecalenone isolated from *Tinosporacrispa*. *J. Ethnopharmacol*. 2002;83:95-99.
- [17] Choudhary MI, Ismail M, Ali Z, Shaari K, Lajis NH, Atta-ur-Rahman Alkaloidal constituents of *Tinosporacrispa*. *Nat Prod Commun*. 2010;5(11):1747-50.
- [18] Akhlaghi M, Bandy B. Mechanisms of flavonoid protection against myocardial ischemia-reperfusion injury. *Journal Molecular and Cellular Cardiology*. 2009;46(3):309-17.
- [19] Halliwell IB, Gutteridge JMC. *Free Radicals in Biology and Medicine*, Oxford, UK: Oxford University Press; 1998:23-64.
- [20] Mishra A, Kumar S, Pandey AK. Scientific validation of the medicinal efficacy of *Tinosporacordifolia*. *The Scientific World Journal*. 2013;2013:1-8.
- [21] Topcua T, Ertasb A, Kolakb U, Öztürk M, Ulubelen A. Antioxidant activity tests on novel Triterpenoids from *salvia macrochlamys*. *ARKIVOC*. 2007;7:195-208.
- [22] Bastona E, Leroux FR. Inhibitors of steroidal cytochrome P450 enzymes as targets for drug development. *Recent Patents on Anti-Cancer Drug Discovery*. 2007;2(1):31-58.
- [23] Hardiningtyas SD, Purwaningsih S, Handharyani E. Antioxidant activity and hepatoprotective effect of green mangrove leaves. *JPHPI*. 2014;17(1):80-91.

PARTICULARS OF CONTRIBUTORS:

1. Faculty, Department of Medicine, Universitas Muhammadiyah, Surakarta, Indonesia.
2. Faculty, Department of Medicine, Universitas Muhammadiyah, Surakarta, Indonesia.
3. Faculty, Department of Medicine, Universitas Muhammadiyah, Surakarta, Indonesia.

NAME, ADDRESS, E-MAIL ID OF THE CORRESPONDING AUTHOR:

Em Sutrisna,
Faculty, Department of Medicine, Universitas Muhammadiyah, Surakarta, Indonesia.
E-mail: Em.Sutrisna@ums.ac.id; em_sutrisna@yahoo.com

FINANCIAL OR OTHER COMPETING INTERESTS: None.

Date of Submission: **Feb 04, 2018**
Date of Peer Review: **Mar 20, 2018**
Date of Acceptance: **May 26, 2018**
Date of Publishing: **Sep 01, 2018**